Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.

Cottin V, Azuma A, Raghu G, Stansen W, Stowasser S, Schlenker-Herceg R, Kolb M.

Eur Respir J. 2019 Jan 17. pii: 1801655. doi: 10.1183/13993003.01655-2018. [Epub ahead of print] No abstract available.

PMID:
30655282
2.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
3.

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.

Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G.

Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.

4.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

5.

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.

Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker-Herceg R, Schmid U, Schnell D, Dallinger C.

J Clin Pharmacol. 2017 Nov 6. doi: 10.1002/jcph.1025. [Epub ahead of print]

6.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

7.

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.

Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM.

Eur Respir J. 2017 May 19;49(5). pii: 1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.

8.

Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Taniguchi H, Xu Z, Azuma A, Inoue Y, Li H, Fujimoto T, Bailes Z, Schlenker-Herceg R, Kim DS.

Respirology. 2016 Nov;21(8):1425-1430. doi: 10.1111/resp.12852. Epub 2016 Jul 11.

9.

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85. doi: 10.1164/rccm.201602-0402OC.

10.

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.

Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, Manuel RC, Schlenker-Herceg R, Bleecker ER.

BMC Pulm Med. 2016 Apr 30;16(1):65. doi: 10.1186/s12890-016-0223-3.

11.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.

12.

Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?

Richeldi L, Le Maulf F, Schlenker-Herceg R, Collard HR.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):1020-1. doi: 10.1164/rccm.201507-1354LE. No abstract available.

PMID:
26469847
13.

Nintedanib: from discovery to the clinic.

Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.

J Med Chem. 2015 Feb 12;58(3):1053-63. doi: 10.1021/jm501562a. Epub 2015 Jan 14. Review.

PMID:
25474320
14.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

15.

Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.

Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S, Lo KH, Barnathan ES; Sarcoidosis Investigators.

Chest. 2009 Aug;136(2):526-535. doi: 10.1378/chest.08-1876. Epub 2009 Apr 24.

PMID:
19395578
16.

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.

Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators.

Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8.

PMID:
19136369
17.

Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems.

Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, Barnathan ES.

Am J Clin Dermatol. 2008;9(3):155-61.

PMID:
18429644
18.

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.

Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J; COPD Investigators.

Am J Respir Crit Care Med. 2007 May 1;175(9):926-34. Epub 2007 Feb 8.

PMID:
17290043
19.

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Müller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES; Sarcoidosis Investigators.

Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. Epub 2006 Jul 13.

PMID:
16840744

Supplemental Content

Loading ...
Support Center